KYNB
Kyntra Bio, Inc.
1W: +2.3%
1M: -9.1%
YTD: -22.2%
$7.13
-0.17 (-2.33%)
After Hours: $7.33 (+0.20, +2.81%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$28.8M
52W Range4.85-12.6
Volume31,994
Avg Volume31,950
Beta0.85
Dividend—
Analyst Ratings
Company Info
CEOThane Wettig
Employees225
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2014-11-14
Websitekyntrabio.com
350 Bay Street
San Francisco, CA 94133
US
San Francisco, CA 94133
US
415 978 1200
About Kyntra Bio, Inc.
Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.
Latest News
Kyntra Bio (KYNB) Q4 2025 Earnings Call Transcript
FibroGen GAAP EPS of -$3.51 beats by $0.37, revenue of $1.27M misses by $0.4M
Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Here are the major earnings after the close Monday
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Wettig Thane | F-InKind | 277 | $6.84 | 2026-03-06 |
| DeLucia David | F-InKind | 60 | $6.84 | 2026-03-06 |
| Wettig Thane | A-Award | 60,000 | $8.50 | 2026-02-03 |
| DeLucia David | A-Award | 26,000 | $8.50 | 2026-02-03 |